Clinical trials: Prostate Cancer Patients Treated by Radiotherapy
Prostate Cancer
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00936390
- Testing
- bicalutamide, flutamide, LHRH agonist (antagonist) therapy
- Where
- 518 sites in United States, Canada
- Volunteers
- 1,538 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Prostate Cancer - Patient Empowerment Program
Each year over 20,000 men are diagnosed with prostate cancer in Canada with the majority undergoing some form of treatment option.
- Trial name
- PC-PEP (NCT03660085)
- Testing
- PC-PEP
- Where
- Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00547339
- Testing
- stereotactic body radiation therapy (SBRT)- 45 Gy, stereotactic body radiation therapy (SBRT) - 47.5 Gy, stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)
- Where
- 5 sites in United States
- Volunteers
- 94 people
- Sponsor
- University of Texas Southwestern Medical Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00321698
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
The study is being done to find out whether combining two FDA approved drugs along with radiation therapy for the treatment of high risk localized prostate cancer is safe and well tolerated.
- Trial name
- NCT02064582
- Testing
- Enzalutamide, Leuprolide acetate, radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Conditions
- Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01434290
- Testing
- 36.25 Gy IMRT, 51.6 Gy IMRT
- Where
- 37 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Sexual Dysfunction
Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in standard radiation therapy) may reduce damage to healthy…
- Conditions
- Prostate Cancer, Sexual Dysfunction, Sexuality and Reproductive Issues
- Trial name
- NCT00084552
- Testing
- radiation therapy
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Fox Chase Cancer Center
Recurrent Prostate Carcinoma, Stage I Prostate Cancer
Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
This randomized phase II trial studies how well metformin hydrochloride and aspirin work in treating patients with hormone-dependent prostate cancer that has progressed after surgery or radiation therapy.
- Conditions
- Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- PRIMA (NCT02420652)
- Testing
- Aspirin, Laboratory Biomarker Analysis, Metformin Hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT01368588
- Testing
- three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy
- Where
- 478 sites in United States, Canada and 4 more
- Volunteers
- 2,590 people
- Sponsor
- Radiation Therapy Oncology Group
Bone Metastases, Multiple Myeloma
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
- Trial name
- NCT00656305
- Testing
- ExAblate MRfFUS
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 147 people
- Sponsor
- InSightec
Prostate Cancer
Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor…
- Trial name
- NCT00714753
- Testing
- brachytherapy, hypofractionated radiation therapy, image-guided radiation therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Adenocarcinoma of the Prostate, Bone Metastases
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating patients with hormone-resistant metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01807065
- Testing
- sipuleucel-T, external beam radiation therapy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00619515
- Testing
- questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
This phase II trial studies how well apalutamide works in treating patients with prostate cancer before radical prostatectomy. Androgen can cause the growth of prostate cancer cells.
- Trial name
- NCT03412396
- Testing
- Apalutamide, Quality-of-Life Assessment, Radical Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
RATIONALE: Specialized radiation therapy that delivers a high-dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00528866
- Testing
- bicalutamide, docetaxel, flutamide
- Where
- 70 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
The primary objective of the study was to compare the efficacy of brachytherapy versus brachytherapy + triptorelin 22.5 mg (single injection) in subjects with recurrence of prostate cancer previously treated with radiotherapy.
- Trial name
- ANABRAQ (NCT01374087)
- Testing
- Triptorelin 22.5 mg, Brachytherapy
- Where
- 11 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Ipsen
Prostate Cancer
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Selenomethionine may slow the growth of prostate cancer. Testosterone can cause the growth of prostate cancer cells. Finasteride may fight prostate cancer by lowering the amount of testosterone the body makes.
- Trial name
- NCT00736645
- Testing
- selenomethionine, finasteride
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Evaluate Recovery of Testosterone for Patients Using Eligard
The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.
- Trial name
- Eligard (NCT01136226)
- Testing
- Eligard (TM)
- Volunteers
- 42 people
- Sponsor
- Chesapeake Urology Research Associates